Track record · closed signal

Halozyme Therapeutics, Inc. (HALO) — closed signal from September 20, 2025

Partial Published before the outcome was known, scored automatically when the window closed on December 19, 2025.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted
$77.81 Published $91.04 Target $67.35 Window close $79.50 Peak
$74.50 – $77.50Entry zone — fair-value band
$77.81Published — price the day we called it
$91.04Target — the price the thesis aimed for
$79.50Peak — highest point inside the window, not a realized return
$67.35Window close — end-of-window price, context only

What happened

Partial

Reached 13% of the predicted growth at its peak, without hitting the target.

Peak price
$79.50
peak on September 23, 2025 — not a realized return
Peak gain
+2.2%
peak, from the publication price
Window close
$67.35
end-of-window price, context only
Days to target
—
Window
September 20, 2025 – December 19, 2025

The thesis — published September 20, 2025

Predicted growth
+17%
over the measurement window
Target price
$91.04
the price the thesis aimed for
Entry zone
$74.50 – $77.50
the fair-value band we waited for
Price at publication
$77.81
published September 20, 2025
Confidence
74%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

HALO offers steady growth with fewer big swings. Analysts raised their estimates, and Morgan Stanley moved its price target to $80. Royalties from the ENHANZE platform and new partner drug launches add reliable cash flow. Near term, strength looks softer, so buying small pullbacks near the recent average price may be better than chasing jumps. If the market stays friendly, modest gains over 1-3 months are reasonable.

Primary drivers

  • Royalties from ENHANZE and new partner drugs can steadily lift sales
  • Analysts are raising estimates, and price targets are moving higher
  • Price trends look healthy overall even if short-term momentum is softer
  • Biotech name with a growth story that tends to hold up in choppy markets

How it played out

HALO: the target was not reached

Lyra published HALO at $77.81 on 2025-09-20 with a short-term view for 17% growth. The thesis pointed to ENHANZE royalties, new partner drug launches, higher analyst estimates, rising price targets, healthy price trends, and a biotech growth story that could hold up in choppy markets.

Inside the window, HALO peaked at $79.50 on 2025-09-23, a 2.2% gain. That stayed below the $91.04 target. The signal ended at $67.35 on 2025-12-19. The thesis only partially played out early, then missed the full target.

What happened during the window

Investors.com reported that Halozyme released third-quarter results on 2025-11-03. The same article said that on 2025-11-12, HALO's Relative Strength Rating rose to 82.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals